Atorvastatin is Hydroxymethylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitor.
VASOBEST Tablets can be used in the treatment of the following indications:
- Coronary heart disease (CHD)
- To reduce the risk of myocardial infarction (MI), stroke, angina, and revascularization procedures.
- To reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS).
- Primary hypercholesterolemia and mixed dyslipidemia
- Homozygous familial hypercholesterolemia
- Primary dysbetalipoproteinemia, and/or hypertriglyeridemia as an adjunct to dietary therapy
Hyperlipidemia (Heterozygous Familial And Nonfamilial) And Mixed Dyslipidemia:VASOBEST Tablets 10 or 20mg once daily. Patients who require a large reduction in LDL-C (more than 45%) may be started at two VASOBEST Tablets 20mg once daily. The dosage range is 10 to 80 mg OD.
Heterozygous Familial Hypercholesterolemia In Pediatric Patients (10-17 yrs of age): VASOBEST Tablets10 mg/day. The maximum recommended dose is VASOBEST Tablets 20 mg/day.
Homozygous Familial Hypercholesterolemia: VASOBEST Tablets10mg to 80mg daily.
Concomitant Lipid-Lowering Therapy: It may be used with bile acid resins.
Atorvastatin selectively and competitively inhibits the hepatic enzyme HMG-CoA reductase. As HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthesis pathway, this results in a subsequent decrease in hepatic cholesterol levels. Decreased hepatic cholesterol levels stimulates upregulation of hepatic LDL-C receptors which increases hepatic uptake of LDL-C and reduces serum LDL-C concentrations.